As of Thursday, the city of Los Angeles had vaccinated 152,612 people against COVID-19 at five city-run vaccination sites. The problem, Los Angeles Mayor Eric Garcetti said, is supply. The city needs more vaccines.

Though California has said eligibility may go by age, Garcetti asked for flexibility Thursday so the city can get vaccines into communities where people are disproportionately dying -- specifically communities of color.

"The next group designated to be moved into receiving the vaccines in the coming weeks will be our workers in emergency services, as well as food and education and child care," Garcetti said.

The city has increased vaccine rollout by 17% since last week, Garcetti said, and its Dodger Stadium site is vaccinating 12,000 people per day. The entire county received 137,000 doses this week and expects 188,000 next week, according to Los Angeles County Public Health Director Dr. Barbara Ferrer.

"The city has distributed 81% of the doses that we have received," the mayor said. "This number is among the highest in the country, higher than many of our peer cities."

COVID-19 stats continue to improve in the hardest-hit county in America. Hospitalizations were down 3% and cases were down 3.4% from Wednesday, Garcetti said. However, Los Angeles County still reported 273 deaths from the disease on Thursday, crossing 16,000 total.

ABC News' Cammeron Parrish contributed to this report.

Tampa Mayor Jane Castor signed an executive order Thursday requiring the use of face coverings at outdoor Super Bowl-related activities to help mitigate the spread of COVID-19 in the Florida city.

The order targets sites where large crowds of people are likely to congregate around the Super Bowl this weekend, with limited ability to remain socially distant from each other. They include "Event Zones" in areas of downtown Tampa and surrounding Raymond James Stadium, as well as "Entertainment Districts," including Ybor City Historic District, the South Howard Commercial Overlay District, the Central Business District and the Channel District.

Those exempt from the order include children under the age of 5, someone communicating with a hearing-impaired individual and people with existing health conditions who would be impaired by a mask.

The Super Bowl will be held on Feb. 7 between the Kansas City Chiefs and hometown Tampa Bay Buccaneers. The mask mandate is in effect now through Feb. 13. Those who violate it could be subject to a $500 fine.

The NFL had previously announced that masks will be required in the stadium unless eating or drinking.

Under a previous order still in effect, masks are required in Tampa at indoor locations outside the home when social distancing cannot be maintained.

ABC News' Will McDuffie contributed to this report

California had its second-deadliest day of the coronavirus pandemic on Wednesday, with 737 additional fatalities from COVID-19.

The deadliest day was Jan. 21 when 764 deaths from the disease were recorded, according to data from the California Department of Public Health.

This comes as the daily number of new COVID-19 cases has dropped considerably in the Golden State.

California's seven-day positivity rate for COVID-19 tests currently stands at 7.9%.

ABC News’ Bonnie Mclean contributed to this report.

The U.S. Department of Health and Human Services has amended rules on who can administer COVID-19 vaccines to address potential shortages.

Any retired nurse or doctor whose license expired in the past five years can now be brought back to give the shot, and anyone licensed or certified to give a COVID-19 vaccine in their state can do so in other states.

ABC News’ Anne Flaherty contributed to this report.

American biotechnology company Regeneron Pharmaceuticals announced Wednesday that its cocktail of two monoclonal antibodies held up in laboratory experiments against new variants of the novel coronavirus first identified in the United Kingdom and South Africa.

Monoclonal antibodies are synthetic versions of our natural antibody defense to infection. They are being studied as a way to both treat and prevent COVID-19 infection, with promising results. But unlike vaccines, which are thought to offer broader protection, some scientists have been worried that this type of therapy would be less effective against newly emerging variants of the virus.

Wednesday's announcement is good news for Regeneron's monoclonal antibody treatment, REGEN-COV, though the data is still preliminary and currently under peer review.

Regeneron scientists as well as researchers at Columbia University in New York City have each independently confirmed that the casirivimab and imdevimab antibody cocktail successfully neutralized both the U.K. and South Africa variants when tested against them, according to a company press release.

REGEN-COV has not yet been tested against another variant that was first identified in Brazil. However, Regeneron said the two-antibody cocktail "is expected to remain similarly potent" based on some resemblance which the Brazil variant bears to the South Africa strain. The company said it is pursuing further confirmatory research.

It's the latest piece of promising news about the efficacy of monoclonal antibodies as treatment for COVID-19. On Tuesday, American pharmaceutical firm Eli Lilly and Company announced that a combination of two monoclonal antibodies, bamlanivimab and etesevimab, was found to be effective in COVID-19 patients at high risk of severe infection, reducing the risk of hospitalization and death by 70%, according to the results of a final-stage trial.

That same day, Regeneron announced its antibody cocktail had shown positive initial results in prophylactic use -- that is, helping ward off COVID-19 in those who may have been exposed to the virus. Regeneron’s chief scientific officer, Dr. George Yancopoulos, said he hopes the drug "may be able to help break this chain" of active infection and transmission.

Last Thursday, Eli Lilly released data showing bamlanivimab may help prevent disease and stop outbreaks among residents and staff of long-term care facilities.

ABC News' Sasha Pezenik contributed to this report.